Atezolizumab Approaches EU Approval for NSCLC, Urothelial Carcinoma

July 21, 2017 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has taken a positive position on indications for atezolizumab in non–small cell lung cancer (NSCLC) and urothelial carcinoma. Roche announced that the CHMP supports atezolizumab monotherapy for adults with previously-treated, locally advanced or metastatic NSCLC, and for adults with locally advanced or metastatic urothelial carcinoma who … (leggi tutto)